Hematology-American Society of Hematology Education Program

Article	Citations
Your chemo is no good here: management of high-risk MCL	85
When should gene therapy be considered for transfusion-dependent β-thalassemia patients?	73
Labor and delivery: DIC, HELLP, preeclampsia	54
Neurological manifestations of MGUS	51
Inpatient recognition and management of HLH	41
On the horizon: upcoming new agents for the management of ITP	35
The varieties of therapeutic experience: navigating treatment options for patients with PNH	32
Advances in the diagnosis and management of pediatric Langerhans cell histiocytosis and Rosai-Dorfman disease: therapies, biomarkers, and response assessment	28
Challenges and opportunities in the long-term management of immune-mediated TTP	27
Recognizing, defining, and managing CAR-T hematologic toxicities	26
Inherited thrombophilia and recurrent miscarriage: is there a role for anticoagulation during pregnancy?	26
Anticoagulation at the end of life: whether, when, and how to treat	24
Bispecific antibody therapies	24
Mastocytosis demystified	24
Individualized patient care in nodular lymphocyte-predominant Hodgkin lymphoma	23
To consolidate or not to consolidate: the role of autologous stem cell transplantation in MCL	22
Mutation- and MRD-informed treatment decisions for the transplant-eligible AML patient	22
Where do immunotherapies stand in management of acute leukemia in adults?	21
T-cell–based therapies for treating relapsed or refractory mantle cell lymphoma	21
Has PD-1 blockade changed the standard of care for cHL?	20
New therapies in hemophilia: extend the half-life, mimic, or rebalance?	20
Fitness and frailty in myeloma	19
Logistics, risks, and benefits of automated red blood cell exchange for patients with sickle cell disease	19
Minimal intensity conditioning strategies for bone marrow failure: is it time for “preventative” transplants?	19
Divergent paths: management of early relapsed follicular lymphoma	19

How to assess hemostasis in patients with severe liver disease	18
MGCS: where do we stand today?	18
Selecting initial therapy in CLL	17
New approaches to tackle cytopenic myelofibrosis	17
Maintenance after CAR T? Are we there yet? Reducing the risk of relapse after loss of anti-CD19 CAR T - cell persistence in ALL	17
Incidence, mechanism, and consequences of IV iron–induced hypophosphatemia	17
Donor selection, graft engineering, and dosing oh my!	16
BV and beyond: how to incorporate novel agents into PTCL management	15
Hypoxia-inducible factor activators: a novel class of oral drugs for the treatment of anemia of chronic kidney disease	15
Planning GvHD preemptive therapy: risk factors, biomarkers, and prognostic scores	15
Optimizing outcomes in secondary AML	15
What is the optimal strategy for secondary prevention after venous thromboembolism in polycythemia vera?	15
How to manage hemostasis in patients with liver disease during interventions	15
Chronic GVHD: review advances in prevention, novel endpoints, and targeted strategies	15
Troubleshooting heparin resistance	15
Incorporating novel agents into frontline treatment of Hodgkin lymphoma	15
How to diagnose and manage antiphospholipid syndrome	14
The sum of the parts: what we can and cannot learn from comorbidity scores in allogeneic transplantation	14
What's new in hereditary hemorrhagic telangiectasia?	14
Mitigating, monitoring, and managing long-term chemotherapy- and radiation-induced cardiac toxicity	14
All shades of gray in the mediastinum: do we have bright ideas about how to diagnose and treat mediastinal gray zone lymphoma in the era of targeted agents?	14
Hematology 2022—what is complete HLA match in 2022?	14
Management of TKI-resistant chronic phase CML	14
With BiTEs at the kiddie table, where do CARs come in for pediatric B-ALL?	14
Demystifying autoimmune HIT: what it is, when to test, and how to treat	13
Nze C, Flowers CR. Barriers to accessing cellular therapy for patients receiving care in community practices. Hematology Am Soc Hematol Educ Program. 202	13
Revisiting novel genomic classifiers in the era of immunotherapy for pediatric B-ALL	13
CAR T-cell therapy and bispecific antibodies in the management of multiple myeloma	13
Consumptive coagulopathy in the ICU	13
Special considerations in GI bleeding in VWD patients	12
Evaluating patients with autoimmune hemolytic anemia in the transfusion service and immunohematology reference laboratory: pretransfusion testing challenges and best transfusion-management strategies	12
Approaches to management of HIT in complex scenarios, including cardiac surgery	12
Management of marginal zone lymphomas	12
Atypical CML: diagnosis and treatment	12
Management of limited-stage Hodgkin lymphoma	12
Transplant in AML with measurable residual disease: proceed or defer?	11
Organ function indications and potential improvements following curative therapy for sickle cell disease	11
Pregnancy management for patients with bleeding disorders	11
Thrombosis questions from the inpatient wards	11
The evolving frontline management of CLL: are triplets better than doublets? How will we find out?	11
Gene transfer and genome editing of T cells for cancer immunotherapy: from allogeneic HSCT to TCR gene editing	11
Identifying Castleman disease from non-clonal inflammatory causes of generalized lymphadenopathy	11
Management of autoimmune hemolytic anemia	11
CNS prophylaxis in aggressive B-cell lymphoma	11
Alloimmunization and hyperhemolysis in sickle cell disease	10
How to evaluate the patient with a suspected mast cell disorder and how/when to manage symptoms	10
Should older patients with low weight and CKD receive full-dose DOACs for treatment of acute proximal DVT?	10
Targeting hardship: poverty as a modifiable risk factor in childhood leukemia and lymphoma treatment	10
Pyruvate kinase activators: targeting red cell metabolism in sickle cell disease	10
Treatment of VTE in the thrombocytopenic cancer patient	10

Nontransplant treatment approaches for myeloid neoplasm with mutated TP53	10
Adolescents and young adults (AYAs) vs pediatric patients: survival, risks, and barriers to enrollment	10
Pegylated interferon: the who, why, and how	10
Cytoreduction for ET and PV: who, what, when, and how?	10
Managing pregnancy in patients with sickle cell disease from a transfusion perspective	9
POEMS syndrome: diagnosis, treatments, and outcomes	9
What makes a pediatric or young adult patient an appropriate transplant candidate?	9
The challenge of deintensifying chemotherapy for children and adolescents with B-ALL in the immunotherapy era	9
Future directions in transplantation for aplastic anemia	9
What is the role of up-front autologous stem cell transplantation in mantle cell lymphoma?	9
When immature plasma cells form lymphoma: how to improve on diagnostics and treatment of plasmablastic lymphoma?	9
Selecting the best treatment approach and optimizing sequencing strategies in large B-cell lymphoma	9
Ph− ALL: immunotherapy in upfront treatment	9
Long-term outcome and management of complement-mediated thrombotic microangiopathy/aHUS	9
Clinical manifestations of telomere biology disorders in adults	9
What is the ideal approach—doublet, triplet, or quadruplet(s)?	9
Monoclonal-related neuropathies: diagnosis, prognosis, and outcomes	9
Thrombocytopenia in pregnancy	9
Monoclonal gammopathy of renal significance from a hematologic perspective	9
Demystifying the diagnosis and management of ICUS, CHIP, and CCUS	9
Next-generation therapy for lower-risk MDS	9
Novel therapies and combinations in CLL refractory to BTK inhibitors and venetoclax	8
Should we use bisphosphonates to treat bone complications in sickle cell disease?	8
Managing side effects: guidance for use of immunotherapies in multiple myeloma	8
Managing patients with a history of arterial disease and new venous thromboembolism	8
Approach to the patient with suspected hypereosinophilic syndrome	8
What to know about rare B-cell malignancies in 2025	8
Sequencing bispecific antibodies and CAR T cells for FL	8
The role of stem cell transplant (auto and allo) in PTCL and CTCL	8
Thrombocytopenia and liver disease: pathophysiology and periprocedural management	7
Stem cell transplantation for ALL: you've always got a donor, why not always use it?	7
Barriers to accessing cellular therapy for patients receiving care in community practices	7
How to classify risk based on clinical and molecular modeling: integrating molecular markers in the risk assessment of myelodysplastic syndrome	7
Molecular surprises in evaluations of red cell disorders	7
Are transplant indications changing for myelofibrosis?	7
Implementation failure: thromboprophylaxis in ambulatory patients with cancer	7
Warm autoimmune hemolytic anemia and the best treatment strategies	7
IV iron formulations and use in adults	7
Novel therapies upon failure of HMA plus venetoclax	7
What is the best induction for myeloma for the fit patient?	7
When it's not Glanzmann thrombasthenia or Bernard-Soulier syndrome: diagnosing other qualitative platelet disorders	7
Updates in antithrombotic therapy in coronary and peripheral artery disease	7
von Willebrand disease and heavy menstrual bleeding: when and how to test	7
Porphyria cutanea tarda: a unique iron-related disorder	7
The aging hemophilia patient	7
In 2022, which is preferred: haploidentical or cord transplant?	7
Posttransplant cells for the win? DLI and adoptive cell therapy to eradicate MRD	7
The approach of HMA plus VEN with or without BMT for all patients with AML	7
Sequencing therapy in relapsed DLBCL	7
Proactive management to improve outcomes of high-risk pregnancy in people with sickle cell disease	7
Evolving landscape of JAK inhibition in myelofibrosis: monotherapy and combinations	6
Novel platelet products including cold-stored platelets	6
Clonal hematopoiesis in frequent whole blood donors	6
Posttransplant complications in patients with marrow failure syndromes: are we improving long-term outcomes?	6
The spectrum of Ph-negative disease: CNL and CSF3R-related disorders	6
Targeted triplet therapies incorporating FLT3 or IDH inhibitors: ready for prime time?	6
Risk-stratification in frontline CLL therapy: standard of care	6
From treatment to biology and back: managing iron overload in transfused hemoglobinopathies	6
Luspatercept: a treatment for ineffective erythropoiesis in thalassemia	6
When should we use it? The role of brentuximab vedotin in 2024	6
Long-term prophylaxis: what are our options and how to define success?	6
Diagnosis of bleeding disorder of unknown cause: how many tests are enough to diagnose BDUC?	6
Management of Fanconi anemia beyond childhood	6
Amyloid consults do not have to be vexing	6
Intravenous iron therapy in pediatrics: who should get it and when is the right time?	6
Understanding differential technologies for detection of MRD and how to incorporate into clinical practice	6
Evidence-Based Minireview: How to utilize new therapies for sickle cell disease	6
Diagnosis and management of cold agglutinin disease	6
Updates in the management of newly diagnosed chronic lymphocytic leukemia	6
New definitions for antiphospholipid syndrome: ready for clinical use?	6
Hormone-related thrombosis: duration of anticoagulation, risk of recurrence, and the role of hypercoagulability testing	5
(Un) Diagnosing von Willebrand disease	5
Multiple myeloma: a paradigm for blending community and academic care	5
Newborn screening initiatives for sickle cell disease in Africa	5
No crystal stair: supporting fertility care and the pursuit of pregnancy in women with sickle cell disease	5
Selection of bispecific antibody therapies or CAR-T cell therapy in relapsed lymphomas	5
Using disease-modifying therapies in sickle cell disease	5
Clonal evolution in inherited marrow failure syndromes predicts disease progression	5
The intersection of sickle cell disease, stigma, and pain in Africa	5
Hitting the brakes on accelerated and blast-phase myeloproliferative neoplasms: current and emerging concepts	5

The first relapse in multiple myeloma: how to pick the next best thing	5
Renal manifestations of MGUS	5
New investigational combinations for higher-risk MDS	5
When to consider inherited marrow failure syndromes in adults	5
Molina JC, Rotz S. Acute lymphoblastic leukemia in young adults: which up-front treatment? Hematology Am Soc Hematol Educ Program. 2023;2023(1):573-580.	5
Novel clinical care models for patients with sickle cell disease	4
Maintenance strategies for relapse prevention and treatment	4
Ph+ ALL: new approaches for upfront therapy	4
Sickle cell disease in India: the journey and hope for the future	4
Transplantation in CML in the TKI era: who, when, and how?	4
Platton S, Sivapalaratnam S, Raheja P. Diagnosis and laboratory monitoring of acquired hemophilia A. Hematology Am Soc Hematol Educ Program. 2023;2023(1):11-18.	4
Hemophagocytic lymphohistiocytosis: do we have a solution for TMI (too much inflammation)?	4
How to manage ITP with life-threatening bleeding	4
New age HCT conditioning regimens: what works and why?	4
Ph+ ALL in 2022: is there an optimal approach?	4
Epidemiology and treatment of priapism in sickle cell disease	4
Challenges to successful outcomes in AYAs with ALL and potential solutions	4
End-of-life care for people with sickle cell disease: barriers to and facilitators of high-quality care	4
Evidence-Based Minireview: Full dose, modified dose, or no anticoagulation for patients with cancer and acute VTE and thrombocytopenia	4
Considerations for next therapy after anti-CD38 monoclonal antibodies used as first line	4
Acute lymphoblastic leukemia in young adults: which up-front treatment?	4
Novel investigational approaches for high-risk genetic subsets of AML: TP53, KMT2A, FLT3	4
Knowledge to date on secondary malignancy following hematopoietic cell transplantation for sickle cell disease	4
Current use of bispecific antibodies to treat multiple myeloma	4
Sharing is caring: a network collaborative approach to identify and address barriers in accessing clinical trials in adolescents and young adults with leukemia and lymphoma	4
Thilagar B, Beidoun M, Rhoades R, Kaatz S. COVID-19 and thrombosis: searching for evidence. Hematology Am Soc Hematol Educ Program. 2021;2021:621-627.	4
Mitigating and managing infection risk in adults treated with CAR T-cell therapy	4
Potential and emerging therapeutics for HHT	4
Optimal approach to T-cell ALL	3
Should posttransplant cyclophosphamide be considered standard of care for pediatric transplantation of acute leukemia?	3
Cellular therapy for multiple myeloma: what's now and what's next	3
Platelet components and bacterial contamination: hospital perspective 2022	3
Novel approaches to acute graft-versus-host disease prevention	3
Endless possibilities and how to exploit them? What is the optimal treatment sequence?	3
Buckle up! Managing surgery in patients with bleeding disorder of unknown cause	3
Thrombopoietin receptor agonists for chemotherapy-induced thrombocytopenia: a new solution for an old problem	3
The range of haploidentical transplant protocols in sickle cell disease: all haplos are not created equally	3
Quantifying menorrhagia and overview of nonsurgical management of heavy menstrual bleeding	3
Dual-targeted regimens for the frontline treatment of CLL	3
Late complications and long-term care of adult CAR T-cell patients	3
Thrombosis and anticoagulation: clinical issues of special importance to hematologists who practice in Asia	3
Iron overload in acquired sideroblastic anemias and MDS: pathophysiology and role of chelation and luspatercept	3
Deconstructing gene therapy in hemophilia for the clinician	3
Givosiran: a targeted treatment for acute intermittent porphyria	3
Catastrophic antiphospholipid syndrome: a CAPS-tivating hematologic disease	3
Optimizing the “right” patient selection for treatment for sickle cell disease	3
Sex, lies, and iron deficiency: a call to change ferritin reference ranges	3
The role of MRD monitoring and options for CLL management in relapsed/refractory disease	3
Patient-reported outcomes after CAR T-cell therapy in patients with hematological malignancies	3
High-grade B-cell lymphomas: high difficulties to diagnose and treat?	3
Beyond FAScinating: advances in diagnosis and management of autoimmune lymphoproliferative syndrome and activated PI3 kinase δ syndrome	3
Identifying and treating iron deficiency anemia in pregnancy	3